Results 61 to 70 of about 493,830 (358)

Diagnostic value of R wave in aVL lead in left ventricular hypertrophy

Universidad Médica Pinareña, 2020
Introduction: left ventricular hypertrophy (LVH) is defined as the increase in the thickness of the wall or the interventricular septal portion (or both). This entity represents an important risk factor that is related to the increase in mortality.
Daniel Alejandro Denis-Piedra, Sheila Martínez-Gutiérrez, Albert Ramón Figueredo-Gilbert, Elia de la Caridad Rodríguez-Venegas   +3 more
doaj   +2 more sources

ASSESSMENT OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ESSENTIAL ARTERIAL HYPERTENSION IN A GENERAL PRACTICE

Zdravniški Vestnik, 2004
Background. The heart is a target organ in arterial hypertension. Echocardiography is the most valuable noninvasive method to assess the left ventricular hypertrophy.
Marija Petek Šter, Boris Krajačič
doaj  

Asociación de la hipertrofía ventricular izquierda con eventos cardiacos posteriores a intervencionismo coronario percutáneo. Association of left ventricular hypertrophy with cardiac events after percutaneous coronary intervention. [PDF]

Revista Cubana de Cardiología y Cirugía Cardiovascular, 2011
Introduction: Left ventricular hypertrophy is not included in the prognostic models of cardiacevents after percutaneous coronary intervention.Objective To determine the association of left ventricular hypertrophy with the presenceof cardiac events during
Luis R. Llerena Rojas, María B. Cabalé Vilariño, Amaury Flores Sánchez   +2 more
doaj  

LEFT VENTRICULAR HYPERTROPHY

The Professional Medical Journal, 2015
Cardiovascular system diseases are playing the outstanding role in the cause ofmorbidity and mortality in dialysis patients. Left ventricular hypertrophy is one of the universalstructural abnormalities in patients on regular dialysis.
Bhagwan Das, Rafique Ansari, Santosh Kumar, Shafique-ur-Rehman Memon   +3 more
semanticscholar   +1 more source

Progression and prognostic significance of electrocardiographic findings in patients with cardiac amyloidosis

ESC Heart Failure, Volume 12, Issue 2, Page 809-818, April 2025.
Abstract Aims This study aimed to evaluate the change of the main electrocardiographic (ECG) characteristics and their prognostic role across the main subtypes of cardiac amyloidosis [light‐chain amyloidosis (AL) and hereditary (ATTRv) and wild‐type transthyretin amyloidosis (ATTRwt)].
Alessia Argirò, Mattia Zampieri, Carlotta Mazzoni, Carlo Fumagalli, Michela Baccini, Alessandra Mattei, Alberto Cipriani, Laura De Michieli, Aldostefano Porcari, Gianfranco Sinagra, Marco Merlo, Giacomo Tini, Beatrice Musumeci, Domitilla Russo, Pier Filippo Vianello, Marco Canepa, Roberto Licordari, Gianluca di Bella, Claudio Rapezzi, Federico Perfetto, Francesco Cappelli   +20 more
wiley   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Screening for Fabry Disease in Left Ventricular Hypertrophy: Documentation of a Novel Mutation

Arquivos Brasileiros de Cardiologia, 2015
Background: Fabry disease is a lysosomal storage disease caused by enzyme α-galactosidase A deficiency as a result of mutations in the GLA gene. Cardiac involvement is characterized by progressive left ventricular hypertrophy.
Ana Baptista, Pedro Magalhães, Sílvia Leão, Sofia Carvalho, Pedro Mateus, Ilídio Moreira   +5 more
doaj   +1 more source

Biomarkers of lung congestion and injury in acute heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 781-789, April 2025.
Abstract Acute heart failure (AHF) classification and management are primarily based on lung congestion and/or hypoperfusion. The quantification of the vascular and tissue lung damage is not standard practice though biomarkers of lung injury may play a relevant role in this context.
Marco Guazzi, Gabriele Novello, Francesca Bursi, Anna Caretti, Noemi Furlotti, Ross Arena, Paola Argiento, Julio Núñez, Antoni Bayes‐Genis, Marco Metra   +9 more
wiley   +1 more source

Diabetes, gender, and left ventricular structure in African-Americans: the atherosclerosis risk in communities study

Cardiovascular Ultrasound, 2006
Background Cardiovascular risk associated with diabetes may be partially attributed to left ventricular structural abnormalities. However, the relations between left ventricular structure and diabetes have not been extensively studied in African ...
Liebson Philip R, Benjamin Emelia J, Arnett Donna K, Duncan Bruce B, Foppa Murilo, Manolio Teri A, Skelton Thomas N   +6 more
doaj   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source